Orexo notes significant change in its owner structure

Orexo notes significant change in its owner structure

Uppsala, Sweden, August 26, 2010 - Orexo AB (STO: ORX) notes today that
its shareholder Novo A/S has increased its ownership position in Orexo
by acquiring an additional 1,397,142 shares representing approximately
6.0% of the current outstanding shares of the company. Upon the closing
of the transaction, Novo A/S will own 3,893,184 shares, or approximately
16.7% of Orexo. Furthermore, Novo A/S holds an Orexo convertible bond,
which if converted would represent an additional 2,340,000 shares equal
to approximately 9.1% of the company after conversion, giving Novo A/S a
24.2% share of the total ownership on an as-converted basis.

For further information, contact:
Torbjörn Bjerke, President and CEO
Tel: +46 (0) 708-661990
E-mail: torbjorn.bjerke@orexo.com (torbjorn.bjerke@orexo.com)

Robin Wright, EVP and CFO
Tel: +44 7720 300025
E-mail: robin.wright@orexo.com (robin.wright@orexo.com)

 

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. Based on Orexo's well established and proven
reformulation technologies, Orexo will develop proprietary products
targeted at the Specialty Pharmaceutical market and intend to
commercialise the products itself in major markets. The project
development builds on Orexo's core competences in R&D, which have
previously resulted in several successful products, currently
out-licensed through worldwide partnership agreements to larger
pharmaceutical companies. Orexo has today four products on the market of
which AbstralTM for the treatment of breakthrough pain in cancer
patients is launched in most of Europe. Orexo has its head office
located in Uppsala, Sweden. More information can be found at
www.orexo.com.

 

 

Note:
This is information that Orexo AB (publ.) is required to disclose
pursuant to the Swedish Securities Markets Act. The information was
provided for public release on August 26, 2010 at 17:30 CET.